Article
Requirement for DARPP-32 in mediating effect of dopamine D2 receptor activation.
The European journal of neuroscience - 1 Jul 1999
Nishi A, Snyder G L, Fienberg A A, Fisone G, Aperia A, Nairn A C, Greengard P
Abstract excerpt
It is well documented that dopamine and dopamine D1 agonists convert the protein phosphatase-1 inhibitor, DARPP-32, from its dephosphorylated, inactive form into its Thr34-phosphorylated, active form, and that these effects on DARPP-32 constitute essential components of the mechanism by which dopamine and D1 agonists achieve their biological effects. In contrast to dopamine and D1 agonists, dopamine D2 agonists...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.